Clinical effectiveness of once-daily fluticasone furoate/umeclidinium/vilanterol in usual practice: the COPD INTREPID study design

Effectiveness studies complement conventional randomised controlled trials by providing a holistic view of treatments in the setting of usual clinical practice. We present the protocol for the ongoing INTREPID (INvestigation of TRelegy Effectiveness: usual PractIce Design; ClinicalTrials.gov identifier: NCT03467425) study, a randomised, open-label, 24-week effectiveness study of once-daily fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI; Trelegy) delivered by the ELLIPTA inhaler versus non-ELLIPTA multiple-inhaler triple therapy in patients with chronic obstructive pulmonary disease (COPD) in usual practice settings. INTREPID was designed to provide evidence of FF/UMEC/VI effectiveness in patients with COPD managed in routine healthcare systems across multiple European countries. Between study initiation and end-of-study visits, patients will receive their medication and care as they would ordinarily receive it, from their usual healthcare provider at their usual healthcare centre. Study-specific intervention will be minimal. The primary end-point will be the proportion of COPD assessment test (CAT) responders, defined as a clinically meaningful improvement from baseline of ≥2 units, at week 24. The CAT was chosen as it provides health status information relevant to patients, physicians, health technology agencies and payers. Lung function (forced expiratory volume in 1 s) and critical inhaler errors will also be assessed in a subgroup of patients. The strengths and weaknesses of the protocol and some of the challenges associated with conducting this multicountry study, such as differences in healthcare systems and treatment practices across sites, will also be discussed. The INTREPID COPD study is investigating the real-world effectiveness of fluticasone furoate/umeclidinium/vilanterol delivered by ELLIPTA versus multiple-inhaler triple therapies in Europe. This article presents the protocol and discusses effectiveness studies in COPD. http://bit.ly/2ZzBAo3

[1]  A randomized, open-label, single-visit, crossover study simulating triple-drug delivery with Ellipta compared with dual inhaler combinations in patients with COPD , 2018, International journal of chronic obstructive pulmonary disease.

[2]  Meilan K. Han,et al.  Once‐Daily Single‐Inhaler Triple versus Dual Therapy in Patients with COPD , 2018, The New England journal of medicine.

[3]  O. Usmani,et al.  Critical inhaler errors in asthma and COPD: a systematic review of impact on health outcomes , 2018, Respiratory Research.

[4]  T. Albertson,et al.  The Salford Lung Study: a pioneering comparative effectiveness approach to COPD and asthma in clinical trials , 2017, Pragmatic and observational research.

[5]  D. Lomas,et al.  FULFIL Trial: Once‐Daily Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease , 2017, American journal of respiratory and critical care medicine.

[6]  M. Egger,et al.  Challenges in pragmatic trials: selection and inclusion of usual care sites. , 2017 .

[7]  H. Chrystyn,et al.  Device errors in asthma and COPD: systematic literature review and meta-analysis , 2017, npj Primary Care Respiratory Medicine.

[8]  H. Chrystyn,et al.  A randomised open-label cross-over study of inhaler errors, preference and time to achieve correct inhaler use in patients with COPD or asthma: comparison of ELLIPTA with other inhaler devices , 2017, npj Primary Care Respiratory Medicine.

[9]  D. Price,et al.  Eligibility of real-life patients with COPD for inclusion in trials of inhaled long-acting bronchodilator therapy , 2016, Respiratory Research.

[10]  Catherine Harvey,et al.  Effectiveness of Fluticasone Furoate-Vilanterol for COPD in Clinical Practice. , 2016, The New England journal of medicine.

[11]  O. Usmani,et al.  Patients’ perspectives and preferences in the choice of inhalers: the case for Respimat® or HandiHaler® , 2016, Patient preference and adherence.

[12]  Laura E. Bothwell,et al.  The Emergence of the Randomized, Controlled Trial. , 2016, The New England journal of medicine.

[13]  J. Riley,et al.  The effect of umeclidinium added to inhaled corticosteroid/long-acting β2-agonist in patients with symptomatic COPD: a randomised, double-blind, parallel-group study , 2016, npj Primary Care Respiratory Medicine.

[14]  Timo Siepmann,et al.  Randomized controlled trials – a matter of design , 2016, Neuropsychiatric disease and treatment.

[15]  Dave Singh,et al.  The bronchodilator effects of extrafine glycopyrronium added to combination treatment with beclometasone dipropionate plus formoterol in COPD: A randomised crossover study (the TRIDENT study). , 2016, Respiratory medicine.

[16]  Takefumi Saito,et al.  Triple therapy with salmeterol/fluticasone propionate 50/250 plus tiotropium bromide improve lung function versus individual treatments in moderate-to-severe Japanese COPD patients: a randomized controlled trial – Evaluation of Airway sGaw after treatment with tripLE , 2015, International journal of chronic obstructive pulmonary disease.

[17]  J. Johnston,et al.  A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results , 2015, Trials.

[18]  E. Kerwin,et al.  Efficacy and safety of umeclidinium added to fluticasone furoate/vilanterol in chronic obstructive pulmonary disease: Results of two randomized studies. , 2015, Respiratory medicine.

[19]  N. Roche,et al.  Real-world research and its importance in respiratory medicine , 2015, Breathe.

[20]  J. Wrobel,et al.  Epidemiology and clinical impact of major comorbidities in patients with COPD , 2014, International journal of chronic obstructive pulmonary disease.

[21]  D. Elbourne,et al.  Systematic review of the Hawthorne effect: New concepts are needed to study research participation effects☆ , 2014, Journal of clinical epidemiology.

[22]  S. Kon,et al.  Minimum clinically important difference for the COPD Assessment Test: a prospective analysis. , 2014, The Lancet. Respiratory medicine.

[23]  F. Martinez,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. , 2007, American journal of respiratory and critical care medicine.

[24]  T. Fleming,et al.  Biomarkers and surrogate endpoints in clinical trials , 2012, Statistics in medicine.

[25]  N. Freemantle,et al.  Designing "Real-World" trials to meet the needs of health policy makers at marketing authorization. , 2011, Journal of clinical epidemiology.

[26]  N. Patsopoulos.  A pragmatic view on pragmatic trials , 2011, Dialogues in clinical neuroscience.

[27]  H. Möller.  Effectiveness studies: advantages and disadvantages , 2011, Dialogues in clinical neuroscience.

[28]  E. Wu,et al.  Therapy persistence and adherence in patients with chronic obstructive pulmonary disease: multiple versus single long-acting maintenance inhalers , 2011, Journal of medical economics.

[29]  P. Jones,et al.  Development and first validation of the COPD Assessment Test , 2009, European Respiratory Journal.

[30]  Ian Harvey,et al.  A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers. , 2009, Journal of clinical epidemiology.

[31]  S. Silverman,et al.  From randomized controlled trials to observational studies. , 2009, The American journal of medicine.

[32]  J. Bourbeau,et al.  Patient adherence in COPD , 2008, Thorax.

[33]  P. Rothwell,et al.  Factors That Can Affect the External Validity of Randomised Controlled Trials , 2006, PLoS clinical trials.

[34]  J. Hankinson,et al.  Standardisation of spirometry , 2005, European Respiratory Journal.

[35]  S. Hurd,et al.  Global Strategy for the Diagnosis, Management and Prevention of COPD: 2003 update , 2003, European Respiratory Journal.

[36]  J. Ayanian.  Using administrative data to assess health care outcomes. , 1999, European heart journal.

[37]  B. Dawson-Saunders,et al.  Basic and Clinical Biostatistics , 1993 .

[38]  J. Avorn,et al.  The exclusion of the elderly and women from clinical trials in acute myocardial infarction. , 1992, JAMA.